Directory of funded grants

Filter by

545 results found

Misfolded SOD1 in ALS pathogenesis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

The first genetic cause of ALS to be discovered (in 1993) encoded a mutation in protein called superoxide dismutase 1 (SOD1). Decades later, it is largely agreed upon that the abnormal shape (called misfolding) of SOD1 mutants is at the root of toxicity in some forms of ALS. Traditionally, misfolded…

Study of the impact of glycation on ALS using an in vitro tissue-engineered model of spinal cord

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Tissue engineering is a process that was originally designed and continues to be used for growing cells outside the body, turning them into functional tissues and organs, and applying them for clinical use. Skin grafting and developing new organs for transplant are examples of how tissue engineering are used as…

RGNEF modulates protein misfolding in ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Discoveries made in Canada by the lab of Dr. Michael Strong over the past few years have implicated a protein called Rho guanidine nucleotide exchange factor (RGNEF) both pathologically and genetically in causing ALS. Further study demonstrated that RGNEF could play a role in the abnormal shape (misfolding) and toxicity…

Muscle-targeted therapy for ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    British Columbia

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

In ALS, the disease is characterized by degeneration of motor neurons and an inability of the brain to signal the muscles to move, resulting in paralysis. Over the past decade, it has become clear that motor neurons are not the only cell type involved in the disease process and attempting…

Regulation of endosomal membrane trafficking by C9ORF72 in ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2016

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Dr. Peter McPherson, professor at the Montreal Neurological Institute, McGill University will receive one year of support to work on the connection between the most prominent known cause of ALS, a mutation in a gene called C9ORF72, and a previously unrelated critical cellular function called endosomal membrane trafficking. Endosomal membrane…